Valuation: DiaSorin S.p.A.

Market Cap 3.71B 4.17B 3.46B 3.15B 5.95B 401B 6B 41.88B 16.23B 205B 15.67B 15.33B 658B P/E 2026 *
21.7x
P/E 2027 * 19.1x
Enterprise Value 4.41B 4.97B 4.12B 3.75B 7.08B 478B 7.15B 49.85B 19.32B 244B 18.65B 18.25B 783B EV / Sales 2026 *
3.58x
EV / Sales 2027 * 3.24x
Free-Float
37.17%
Yield 2026 *
1.74%
Yield 2027 * 1.82%
Manager TitleAgeSince
Chief Executive Officer 60 26/03/2007
Director of Finance/CFO - 01/01/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 60 28/04/2016
Director/Board Member 63 26/03/2007
Chairman 57 29/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.17B
+0.84%-3.74%-26.69%+1.85% 169B
-0.07%-2.55%-9.53%+11.07% 110B
+0.90%+1.13%-24.83%+0.58% 106B
-1.24%-0.76%-49.04%-12.75% 73.87B
-0.24%+0.69%+0.16%+72.58% 58.98B
-0.86%+2.96%+13.57%+59.50% 51.28B
-0.71%-3.82%-7.72%-31.41% 48.16B
+0.12%-0.17%-18.21%+20.29% 40.84B
-1.01%-1.45%+28.48%-9.72% 32.21B
Average -0.23%-0.86%-10.42%+12.44% 76.69B
Weighted average by Cap. +0.03%-1.30%-16.36%+10.13%

Financials

2026 *2027 *
Net sales 1.23B 1.39B 1.15B 1.05B 1.98B 133B 2B 13.92B 5.4B 68.19B 5.21B 5.1B 219B 1.31B 1.48B 1.22B 1.12B 2.1B 142B 2.12B 14.8B 5.74B 72.5B 5.54B 5.42B 233B
Net income 183M 206M 171M 155M 293M 19.78B 296M 2.06B 800M 10.11B 772M 756M 32.45B 206M 232M 192M 175M 330M 22.27B 333M 2.33B 901M 11.39B 870M 851M 36.54B
Net Debt 706M 795M 659M 601M 1.13B 76.39B 1.14B 7.97B 3.09B 39.05B 2.98B 2.92B 125B 541M 608M 505M 460M 867M 58.5B 875M 6.11B 2.37B 29.9B 2.28B 2.23B 95.97B
Logo DiaSorin S.p.A.
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
74.90EUR
Average target price
72.81EUR
Spread / Average Target
-2.79%

Quarterly revenue - Rate of surprise